Delving into the Latest Updates on Beijing Tumor Hospital with Synapse

Overview

Tags

Neoplasms

Urogenital Diseases

Digestive System Disorders

Diagnostic radiopharmaceuticals

Peptide Conjugate Radionuclide

Small molecule-drug conjugates

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	6

Top 5 Drug Type	Count

Diagnostic radiopharmaceuticals	4
Peptide Conjugate Radionuclide	2
Herbal medicine	1
Radionuclide Drug Conjugates (RDC)	1
Small molecule-drug conjugates	1

Top 5 Target	Count

PSMA(Prostate-specific membrane antigen)	2
BSG(Basigin)	1
PDL1(Programmed death-ligand 1)	1
CLDN18.2(Claudin 18.2)	1

The treatment efficacy for stage IVb esophageal cancer has been improved through chemotherapy combined with immunotherapy recently.
On this basis, the investigators intend to conduct a prospective, multicenter phase III clinical trial to assess whether radiotherapy with concurrent chemotherapy and immunotherapy could further improve the survival of patients with metastatic esophageal cancer.
Accompanied tissue samples, blood samples and urine samples will be analyzed by molecular biological detection (Including Whole Exome Sequencing and proteomics) to explore potential biomarkers for predicting outcomes, efficacy and toxicity.

Start Date04 Feb 2024

Sponsor / Collaborator

Cancer Hospital Chinese Academy of Medical Sciences

[+12]

NCT06099821 / RecruitingPhase 2IIT

A Phase II Clinical Study Evaluating The Efficacy and Safety of KN046 in Combination With Regorafenib or Apatinib for Microsatellite Instability-High Digestive System Cancers Resistant to PD-1/PD-L1 Blockade

The study is an interventional phase II clinical trial aiming to evaluate the efficacy and safety of KN046, a PD-L1 and CTLA-4 bispecific antibody, in combination with regorafenib or apatinib for microsatellite instability-high digestive system cancers resistant to PD-1/PD-L1 blockade. KN046 plus regorafenib will be given for patients with colorectal cancers, and KN046 plus apatinib will be given for patients with gastric cancers (including esophageal-gastric junction cancers) and other kinds of digestive system cancers.

Start Date25 Oct 2023

Sponsor / Collaborator

Beijing Tumor Hospital

NCT05983237 / Not yet recruitingPhase 1/2IIT

Phase Ib Study of Fluzoparib in Combination With Camrelizumab and Temozolomide in Advanced Melanoma With Homologous Recombination (HR) Mutation ，a Single-center Open-label Exploratory Clinical Trial

The purpose of this study is to evaluate how well fuzoparib in combination with camrelizumab and temozolomide works in treating patients with advanced, metastatic melanoma with the homologous recombination (HR) pathway gene mutation / alteration.

Start Date31 Aug 2023

Sponsor / Collaborator

Beijing Tumor Hospital

100 Clinical Results associated with Beijing Tumor Hospital

Login to view more data

0 Patents (Medical) associated with Beijing Tumor Hospital

Login to view more data

2

Literatures (Medical) associated with Beijing Tumor Hospital

01 Jul 2017·Experimental and Therapeutic MedicineQ4 · MEDICINE

Comparison of the gas-liquid dual support fixation and Heitzman fixation techniques for preparing lung specimens

Q4 · MEDICINE

Article

Author: Qu, Weili ; Yu, Dongsheng ; Yan, Renjie ; Zhao, Peng ; Li, Xiaofeng ; Luan, Zhenfeng ; Lu, Xiaodong ; Xia, Haipeng

The aim of the present study was to compare the gas-liquid dual support fixation and Heitzman fixation techniques for the preparation of lung specimens. A total of 40 fresh lung samples were surgically collected from 40 male patients with lung cancer by biopsy. Patients were recruited from the Affiliated Hospital of Qingdao University Medical College (Qingdao, China) between July 2007 and June 2014. Samples were prepared using either the gas-liquid dual support fixation method (group A; n=26) or the Heitzman fixation method (group B; n=14). High-resolution computed tomography (HRCT) scanning was performed prior to surgery and corresponding postoperative HRCT scanning was conducted for the lung specimens; the gross transverse specimen section, cord photography images and histological sections were evaluated. Morphological observations of lung specimens indicated that there were 22 cases in group A with grade I (84.6%) and 4 cases with grade II (15.4%), whereas, in group B, there were 5 cases with grade II (35.7%) and 9 cases with grade III (64.3%). Statistical analysis demonstrated that the grades of specimens between the two groups were significantly different (P<0.01). Results from imaging and histological studies found that the quality of lung specimens was superior in group A, compared with group B. In conclusion, the present study demonstrated that, compared with the Heitzman fixation method, gas-liquid dual support fixation may be a superior technique for the preparation of lung specimens. This finding may facilitate the improvement of lung HRCT and pathological studies.

20 May 2009·Journal of Clinical Oncology

Longitudinal evaluation of EGFR mutation in plasma for non-small cell lung cancer patients with front-line chemotherapy

Author: Wu, M. N. ; Duan, J. C. ; Wang, S. H. ; Yang, L. ; Wang, J. ; Hua, B. ; Zhao, J.

8099 Background: To investigate longitudinally epidermal growth factor receptor (EGFR) mutation status in the plasma of pre- and post-chemotherapy for patients with advanced non-small cell lung cancer. Methods: Total of 153 advanced lung cancer patients were included in this study. Plasma samples in pre- and post-chemotherapy ( 2 cycles after) were collected. The DNA concentration was determined by real-time PCR. The EGFR exon 19 and 21 were amplified by mutant-enriched PCR and detected by denaturing high performance liquid chromatograph (DHPLC). The associations between EGFR mutation, DNA level and chemotherapeutic response were analyzed. Results: Among the 153 pts, EGFR mutation were detected 41.2% (63/153) and 27.4% (42/153) in plasma of pre-and post-chemotherapy, respectively. The objective response rate was 31.4% (48/153) and the circulating DNA level trend to decrease after chemotherapy in PR group but increase in PD group (p=0.012). 25 and 73 cases showed consistent EGFR mutation and wild-type status in pre-treatment and post-treatment plasma, respectively. Among 38 patients with change from pre-treatment EGFR mutant-type to post-treatment wild-type status, 11 gained PR, 12 SD and 15 PD. While for 17 patients with change from pre-treatment EGFR wild-type to post-treatment mutant-type, PR, SD and PD were 8, 7 and 2, respectively. The change to mutant-type in post-treatment plasma were found to be significantly higher in PR and disease control than PD(P=0.047, P=0.042). Conclusions: The data indicated that chemotherapy could not only affect the DNA concentration but also change the EGFR mutation detection in plasma for pts with advanced NSCLC. Reason for EGFR mutation change related with response of chemotherapy deserves further study. No significant financial relationships to disclose.

100 Deals associated with Beijing Tumor Hospital

Login to view more data

100 Translational Medicine associated with Beijing Tumor Hospital

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 07 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

6

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

18FAl-PSMA-BCH-ZL ( PSMA )	Prostatic Cancer More	Preclinical
Shugan-Liangxue prescription	Neoplasms More	Preclinical
[177Lu]-TST001 ( CLDN18.2 )	Stomach Cancer More	Preclinical
124I-labeled anti-CD147 antibody ( BSG )	Solid tumor More	Preclinical
68Ga-PSMA-BCH ( PSMA )	Prostatic Cancer More	Preclinical